X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (392) 392
Paper (167) 167
Publication (132) 132
Report (70) 70
Data Set (3) 3
Book Review (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cern lhc coll (252) 252
experimental results (243) 243
13000 gev-cms (207) 207
experiment (198) 198
p p: scattering (197) 197
high energy physics - experiment (196) 196
physics (192) 192
p p: colliding beams (181) 181
physics - high energy physics - experiment (168) 168
particle physics (167) 167
high energy physics (159) 159
hep (158) 158
cms (127) 127
ex (114) 114
phenomenology (113) 113
physics of elementary particles and fields (87) 87
humans (81) 81
background (76) 76
hadron-hadron scattering (72) 72
scattering [p p] (70) 70
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (67) 67
index medicus (66) 66
colliding beams [p p] (63) 63
female (60) 60
nuclear experiment (56) 56
breast cancer (54) 54
oncology (54) 54
mass dependence (53) 53
cern lab (51) 51
channel cross section: upper limit (49) 49
channel cross section: branching ratio: upper limit (43) 43
transverse momentum: missing-energy (40) 40
114 physical sciences (39) 39
supersymmetry (39) 39
article (38) 38
middle aged (35) 35
cancer (34) 34
breast neoplasms - drug therapy (33) 33
trastuzumab (33) 33
adult (32) 32
final state:jet lepton (32) 32
astrophysics (31) 31
data analysis method (31) 31
beyond standard model (30) 30
bottom: particle identification (30) 30
breast neoplasms - pathology (30) 30
muon: pair production (30) 30
top: pair production (30) 30
aged (29) 29
chemotherapy (28) 28
nuclear and particle physics. atomic energy. radioactivity (28) 28
research (28) 28
higgs particle: hadroproduction (26) 26
kinematics (26) 26
final state:jet dilepton (25) 25
tumors (25) 25
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (23) 23
analysis (23) 23
hep-ex (23) 23
jet: bottom (23) 23
mutation (23) 23
particle physics - experiment (23) 23
quantum chromodynamics: perturbation theory (23) 23
resonance: production (23) 23
tau: pair production (23) 23
z0: leptonic decay (23) 23
therapy (22) 22
bottom: pair production (21) 21
mass spectrum: (21) 21
narrow resonance (21) 21
physics, particles & fields (21) 21
structure (21) 21
animals (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
cancer therapies (20) 20
care and treatment (20) 20
final state:jet (20) 20
gravitation (20) 20
channel cross section: measured (19) 19
higgs particle: hadronic decay (19) 19
signature (19) 19
electroweak interaction (18) 18
high energy astrophysical phenomena (18) 18
mediation (18) 18
new particle (18) 18
nuclear physics (18) 18
perturbation theory: higher-order (18) 18
upper limit [channel cross section] (18) 18
disease-free survival (17) 17
genetic aspects (17) 17
higher-order: 0 (17) 17
higher-order: 1 (17) 17
male (17) 17
sensitivity (17) 17
transverse momentum (17) 17
treatment outcome (17) 17
cell line, tumor (16) 16
drug therapy (16) 16
higgs particle: doublet (16) 16
higgs physics (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 377 - 384
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 640 - 647
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1137 - 1146
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 461 - 471
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article